- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
What Do Doctors Think About Biosimilars? презентация
Содержание
- 1. What Do Doctors Think About Biosimilars?
- 2. In March 2015, the Alliance for Safe
- 3. The web-based survey was conducted before the
- 4. Powered by Small World Social considered
- 5. Powered by Small World Social it
- 6. Powered by Small World Social It
- 7. Powered by Small World Social It
- 8. In 2013, the ASBM also surveyed 470
- 9. The survey highlighted the lack of awareness
- 10. Powered by Small World Social said
- 11. Powered by Small World Social were
- 12. Powered by Small World Social had never heard of biosimilars 4% of respondents Biolink.us
- 13. Powered by Small World Social were
- 14. Meanwhile, a study conducted by the Tufts
- 15. Powered by Small World Social While
- 16. Powered by Small World Social www.biolink.us Want
In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologics medicines labeling. Powered by Small World
Слайд 2In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released
results from their survey of 400 US physicians on biologics medicines labeling.
Powered by Small World Social
www.biolink.us
Слайд 3The web-based survey was conducted before the FDA approved Zarxio, the
first biosimilar in the US, and sought the view of dermatologists, endocrinologists, oncologists, nephrologists, neurologists and rheumatologists.
It found…
It found…
Powered by Small World Social
www.biolink.us
Слайд 4
Powered by Small World Social
considered it important for a biosimilar’s product
label to clearly indicate that it is a biosimilar.
90% of correspondents
Biolink.us
Слайд 5
Powered by Small World Social
it important for the biosimilar label to
include the biosimilar sponsor’s analytical data demonstrating its analytical similarity to the reference product
82% thought
Biolink.us
Слайд 6
Powered by Small World Social
It important that the biosimilar label includes
the clinical data, if any, submitted to the FDA by the sponsor again demonstrating that it is highly similar to the reference product
83% thought
Biolink.us
Слайд 7
Powered by Small World Social
It important that the label explicitly state
that the specific indications or conditions of use approved for the originator product that are not approved for the biosimilar product
79% found
Biolink.us
Слайд 8In 2013, the ASBM also surveyed 470 European physicians, from the
United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines.
Powered by Small World Social
www.biolink.us
Слайд 9The survey highlighted the lack of awareness about biosimilars amongst prescribing
specialist physicians and the need for further education.
It found…
It found…
Powered by Small World Social
www.biolink.us
Слайд 10
Powered by Small World Social
said they are ‘familiar’ with biosimilars, but
only have a basic understanding
54% of respondents
Biolink.us
Слайд 11
Powered by Small World Social
were unable to define biosimilars
20% of the
physicians
Biolink.us
Слайд 13
Powered by Small World Social
were ‘very familiar’, with a complete understanding
of biosimilars
22% of the physicians
Biolink.us
Слайд 14Meanwhile, a study conducted by the Tufts Center of the Study
of Drug Development, at Tufts University in Boston, found that…
Powered by Small World Social
www.biolink.us
Слайд 15
Powered by Small World Social
While the majority of physicians, 70%, surveyed
said they would be likely to prescribe biosimilars to a new patient, the overall lack of familiarity with the new products among specialist physicians could slow the uptake of biosimilars in the U.S.
Biolink.us
Слайд 16Powered by Small World Social
www.biolink.us
Want to read more about biosimilars?
Visit:
https://www.smallworldsocial.com/biolink/ to
get the latest in biosimilar news curated from around the world
